Why the study?
Transient visual loss associated with patent foramen ovale is a rare presentation with few reported instances in the literature.
Does percutaneous patent foramen ovale closure with dual antiplatelet therapy prevent recurrent transient visual loss and neurological events in a young adult with PFO-associated amaurosis fugax?
Case Report (n=1)
No
Does percutaneous patent foramen ovale closure with dual antiplatelet therapy prevent recurrent transient visual loss and neurological events in a young adult with PFO-associated amaurosis fugax?
Answers are grounded in this paper and cite their sources.
This case report highlights the importance of evaluating for and closing a patent foramen ovale in young patients without traditional vascular risk factors who present with recurrent cryptogenic transient monocular vision loss (amaurosis fugax) to prevent future ischemic events.
Patent foramen ovale (PFO) is a congenital septal defect resulting from the failure of closure of the interatrial communication that normally seals after birth.In conditions leading to a sudden increase in intrathoracic or intraabdominal pressure, right-to-left shunting across the atria may occur, which may lead to cryptogenic stroke in children and young adults without traditional risk factors.An 18-year-old woman experienced sudden unilateral vision loss 6 months ago, and no pathology was detected during the initial ophthalmological and neurological examination.Subsequent cardiac examination and echocardiography revealed a PFO.The patient, who had no comorbidities, attributed the sudden vision loss to the PFO, and percutaneous closure was performed.In patients presenting with transient sudden visual loss, clinicians should consider PFO in the absence of additional risk factors or when no definitive diagnosis can be established.In cases of cryptogenic stroke where the etiology is difficult to determine, it is crucial to evaluate for and manage a patent foramen ovale (PFO) to prevent recurrent strokes and permanent visual impairment.To the best of our knowledge, this case represents one of the few reported instances of transient visual loss associated with PFO in the literature.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) conducted a case report in Recurrent transient monocular visual loss (amaurosis fugax) associated with patent foramen ovale (n=1). Percutaneous patent foramen ovale closure (20 mm Amplatzer Occluder) plus dual antiplatelet therapy was evaluated on Recurrence of transient visual loss, transient ischemic attack, or other neurological events and residual interatrial shunting at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: